Aortic, but not brachial blood pressure category enhances the ability to identify target organ changes in normotensives

Journal of Hypertension

Volumn 31, Issue 6, 2013, Pages 1124-1130

  Booysen, Hendrik L ^a   Norton, Gavin R ^a   Maseko, Muzi J ^a   Libhaber, Carlos D ^b   Majane, Olebogeng H I ^a   Sareli, Pinhas ^a   Woodiwiss, Angela J ^a  

^a UNIVERSITY OF THE WITWATERSRAND MEDICAL SCHOOL   (South Africa)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

aortic BP; normal high normal BP; risk factors; target organ changes

Indexed keywords

ANTIHYPERTENSIVE AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AFRICA; AORTA PRESSURE; APPLANATION TONOMETER; ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE MEASUREMENT; BODY MASS; BRACHIAL ARTERY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAROTID ARTERY PULSE; DIABETES MELLITUS; ESTIMATED GLOMERULAR FILTRATION RATE; FEMALE; GLOMERULUS FILTRATION RATE; HEART LEFT VENTRICLE MASS; HUMAN; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; MAJOR CLINICAL STUDY; MALE; OBESITY; PRIORITY JOURNAL; RISK ASSESSMENT; SYSTOLIC BLOOD PRESSURE; WAIST CIRCUMFERENCE;

EID: 84877574791     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0b013e328360802a     Document Type: Article

References (42)

1. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R, Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360:1903-1913.
2. Vasan RS, Larson MG, Leip EP, Evans JC, O'Donnell CJ, Kannel WB, et al. Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med 2001; 345:1291-1297.
3. Liszka HA, Mainous AG 3rd, King DE, Everett CJ, Egan BM. Prehypertension and cardiovascular morbidity. Ann Fam Med 2005; 3:294-299.
4. Qureshi AI, Suri MF, Kirmani JF, Divani AA, Mohammad Y. Is prehypertension a risk factor for cardiovascular diseases? Stroke 2005; 36:1859-1863.
5. Zhang Y, Lee ET, Devereux RB, Yeh J, Best LG, Fabsitz RR, et al. Prehypertension, diabetes and cardiovascular disease risk in a population-based sample: The Strong Heart Study. Hypertension 2006; 47:410-414.
6. Kshirsagar AV, Carpenter M, Bang H, Wyatt SB, Colindres RE. Blood pressure usually considered normal is associated with an elevated risk of cardiovascular disease. Am J Med 2006; 119:133-141.
7. Hsia J, Margolis KL, Eaton CB, Wenger NK, Allison M, Wu L, et al. Women's Health Initiative Investigators. Prehypertension and cardiovascular disease risk in the Women's Health Initiative. Circulation 2007; 115:855-860.
8. Conen D, Ridker PM, Buring JE, Glynn RJ. Risk of cardiovascular events among women with high normal blood pressure or blood pressure progression: prospective cohort study. BMJ 2007; 335:432-440.
9. Butler J, Kalogeropoulos AP, Georgiopoulou VV, Bibbins-Domingo K, Najjar SS, Sutton-Tyrrell KC, et al. Systolic blood pressure and incident heart failure in the elderly. The Cardiovascular Health Study and the Health, Ageing and Body Composition Study. Heart 2011; 97:1304-1311.
10. Nissen SE, Tuzcu EM, Libby P, Thompson PD, Ghali M, Garza D, et al., CAMELOT Investigators. Effects of antihypertensive agents on cardiovascular events in patients with coronary artery disease and normal blood pressure: the CAMELOT Study: a randomised controlled trial. JAMA 2004; 292:2217-2225.
11. Remme WJ, Deckers JW, Fox KM, Ferrari R, Bertrand M, Simoons ML, EUROPA Investigators. Secondary prevention of coronary artery disease with ACE-inhibition-does blood pressure reduction with perindopril explain the benefits in EUROPA? Cardiovasc Drugs Ther 2009; 23:161-170.
12. PROGRESS Collaborative Group. Randomised trial of a perindoprilbased blood-pressure-lowering regimen study among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 3581:1033-1041.
13. Tumbull F, Blood Pressure Lowering Treatment Trialist Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003; 362:1527-1535.
14. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009; 338:1245-1253.
15. Thompson AM, Hu T, Eshelbrenner CL, Reynolds K, He J, Bazzano LA. Antihypertensive treatment and secondary prevention of cardiovascular disease events among persons without hypertension. JAMA 2011; 305:913-922.
16. Schrier RW, Estacio RO, Esler A, Mehler P. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int 2002; 61:1086-1097.
17. Patel A, MacMahon S, Chalmers J, Neal B, Woodward M, Billot L, et al., ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007; 370:829-840.
18. Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, et al., The ONTARGET Investigators. Telmisartan, ramipril or both in patients at high risk for vascular events? N Engl J Med 2008; 358:1547-1559.
19. Yusuf S, Teo K, Anderson C, Pogue J, Dyal L, Copland I, et al., Telmisartan Randomised AssesmeNt Study in ACE INtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators. Effects of the angiotensin receptor blocker telmisartan on cardiovascular events in high risk patients intolerant of angiotensin-converting enzyme inhibitors: a randomised controlled trail. Lancet 2008; 372:1174-1183.
20. Yusuf F, Diener H-C, Sacco R, Cotton D, Ounpuu S, Lawton WA, et al., PRoFESS Stduy Group. Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med 2008; 359:1225-1237.
21. Cushman WC, Evans GW, Byuington RP, Goff DC, Grimm RH, Cutler JA, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010; 362:1575-1585.
22. Cooper-DeHoff RM, Gong Y, Handberg EM, Bavry AA, Denardo SJ, Bakris GL, et al. Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA 2010; 304:61-68.
23. McMurray JJ, Holman RR, Haffner SM, Bethel MA, Holzhauer B, Hua TA, et al., The NAVIGATOR Study Group. Effects of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med 2010; 362:1477-1490.
24. McEniery CM, Yasmin, McDonnell B, Munnery M, Wallace SM, Rowe CV, et al. Central pressure: variability and impact of cardiovascular risk factors-The Anglo-Cardiff Collaborative Trial II. Hypertension 2008; 51:1476-1482.
25. Safar M, Blacher J, Pannier B, Marchais S, Guyonvarc'h PM, London G. Central pulse pressure and mortality in end-stage renal disease. Hypertension 2002; 39:735-738.
26. Roman MJ, Devereux RB, Kizer JR, Lee ET, Galloway JM, Ali T, et al. Central pressure more strongly relates to vascular disease and outcome than does brachial pressure: the Strong Heart Study. Hypertension 2007; 50:197-203.
27. Jankowsky P, Kawecka-Jaszcz K, Czamecka D, Brzozowska-Kiszka M, Styczkiewicz K, Loster M, et al. Aortic Blood Pressure and Survival Study Group. Pulsatile, but not steady component of blood pressure predicts cardiovascular events in coronary patients. Hypertension 2008; 51:848-855.
28. Chirinos JA, Zambrano JP, Chakko S, Veerani A, Schob A, Willens HJ, et al. Aortic pressure augmentation predicts adverse cardiovascular events in patients with established coronary artery disease. Hypertension 2005; 45:980-985.
29. Pini R, Cavallini MC, Palmieri V, Marchionni N, Bari MD, Devereux RB, et al. Central but not brachial pressure predicts cardiovascular events in an unselected geriatric population. J Am Coll Cardiol 2008; 51:2432-2439.
30. Norton GR, Maseko M, Libhaber E, Libhaber CD, Majane OHI, Dessein P, et al. Is prehypertension an independent predictor of target organ changes in young-to-middle aged persons of African descent? J Hypertens 2008; 26:2279-2287.
31. Redelinghuys M, Norton GR, Scott L, Maseko MJ, Brooksbank R, Majane OHI, et al. Relationship between urinary salt excretion and pulse pressure and central aortic hemodynamics independent of steady state pressure in the general population. Hypertension 2010; 56:584-590.
32. Norton GR, Majane OH, Maseko MJ, Libhaber C, Redelinghuys M, Kruger D, et al. Brachial blood pressure-independent relations between radial late systolic shoulder-derived aortic pressures and target organ changes. Hypertension 2012; 59:885-892.
33. Bennett CM, Guo M, Dharmage SC. HbA (1c) as a screening tool for detection of Type 2 diabetes: a systematic review. Diabet Med 2007; 24:333-343.
34. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation: Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130:461-470.
35. Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, et al. Echocardiograph assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 1986; 57:450-458.
36. Mancia G, de Backer G, Dominiczak A, Cifkova R, Germano G, Grassi G, et al. Management of Arterial Hypertension of the European Society of Hypertension: European Society of Cardiology. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 6:1105-1187.
37. Sehestedt T, Jeppesen J, Hansen TW, Wachtell K, Ibsen H, Torp-Pedersen C, et al. Risk prediction is improved by adding markers of subclinical organ damage to SCORE. Eur Heart J 2010; 31:883-891.
38. Sehestedt T, Jeppesen J, Hansen TW, Rasmussen S, Wachtell K, Ibsen H, et al. Risk stratification with the risk chart from the European Society of Hypertension compared with SCORE in the general population. J Hypertens 2009; 27:2351-2357.
39. Moreira LB, Fuchs SC, Wiehe M, Gus M, Moraes RS, Fuchs FD. Incidence of hypertension in Porto Alegre, Brazil: a population-based study. J Hum Hypertens 2008; 22:48-50.
40. Shimbo D, Newman JD, Schwartz JE. Masked hypertension and prehypertension: diagnostic overlap and interrelationships with left ventricular mass-The Masked Hypertension Study. Am J Hypertens 2012; 25:664-671.
41. Manios E, Michas F, Tsivgoulis G, Stamatelopoulos K, Tsagalis G, Koroboki E, et al. Impact of prehypertension on caroitid intima-media thickening: actual or masked? Atherosclerosis 2011; 214:215-219.
42. Fukuhara M, Arima H, Ninomiya T, Hata J, Yonemotio K, Doi Y, et al. Impact of lower range of prehypertension on cardiovascular events in a general population: the Hisayama Study. J Hypertens 2012; 30:893-900.